Q1

News
astrazeneca-sign

AZ posts solid Q1 results as Alexion merger looms

AstraZeneca's not-for-profit coronavirus vaccine has bit into margins in Q1, although revenues were ahead of expectations as the company heads towards completion of its $39bn acquisition of

News
Sanofi Q1 growth driven by Genzyme

Sanofi Q1 growth driven by Genzyme

Genzyme continued to drive growth for Sanofi in the first quarter, helped along by the company’s vaccines unit, but diabetes drugs are still struggling.